Published in Int J Geriatr Psychiatry on May 01, 2003
Validation of the telephone interview for cognitive status-modified in subjects with normal cognition, mild cognitive impairment, or dementia. Neuroepidemiology (2009) 2.03
Social network, cognitive function, and dementia incidence among elderly women. Am J Public Health (2008) 2.02
Validation of multi-stage telephone-based identification of cognitive impairment and dementia. BMC Neurol (2005) 1.63
Telephone interview for cognitive status: Creating a crosswalk with the Mini-Mental State Examination. Alzheimers Dement (2009) 1.45
Relationship between body height and dementia. Am J Geriatr Psychiatry (2005) 1.12
Validation of the modified telephone interview for cognitive status in amnestic mild cognitive impairment and intact elders. Alzheimer Dis Assoc Disord (2009) 0.91
The Memory and Aging Telephone Screen: development and preliminary validation. Alzheimers Dement (2007) 0.89
Screening by telephone in the Alzheimer's disease anti-inflammatory prevention trial. J Alzheimers Dis (2013) 0.83
Body weight variability in midlife and risk for dementia in old age. Neurology (2013) 0.82
Demographic corrections for the modified telephone interview for cognitive status. Clin Neuropsychol (2013) 0.81
Correcting for demographic variables on the modified telephone interview for cognitive status. Am J Geriatr Psychiatry (2013) 0.80
Repetitive thinking as a psychological cognitive style in midlife is associated with lower risk for dementia three decades later. Dement Geriatr Cogn Disord (2009) 0.79
Exposure to the Holocaust and World War II concentration camps during late adolescence and adulthood is not associated with increased risk for dementia at old age. J Alzheimers Dis (2011) 0.78
Religious education and midlife observance are associated with dementia three decades later in Israeli men. J Clin Epidemiol (2008) 0.78
Forgetting in context: the effects of age, emotion, and social factors on retrieval-induced forgetting. Mem Cognit (2012) 0.77
Late-life dementia predicts mortality beyond established midlife risk factors. Am J Geriatr Psychiatry (2011) 0.77
Middle age self-report risk score predicts cognitive functioning and dementia in 20-40 years. Alzheimers Dement (Amst) (2016) 0.75
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet (2008) 6.24
Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA (2002) 4.91
Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med (2010) 4.42
Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care (2008) 3.65
Advancing paternal age and autism. Arch Gen Psychiatry (2006) 3.58
Superresolution imaging using single-molecule localization. Annu Rev Phys Chem (2010) 3.30
Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol (2008) 3.15
Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry (2005) 2.62
Subgroup interactions in the Heart and Estrogen/Progestin Replacement Study: lessons learned. Circulation (2002) 2.18
Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol (2013) 1.96
A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res (2006) 1.93
Strong synaptic transmission impact by copy number variations in schizophrenia. Proc Natl Acad Sci U S A (2010) 1.85
Family history of schizophrenia and bipolar disorder as risk factors for autism. Arch Gen Psychiatry (2012) 1.76
A population-based cohort study of premorbid intellectual, language, and behavioral functioning in patients with schizophrenia, schizoaffective disorder, and nonpsychotic bipolar disorder. Am J Psychiatry (2002) 1.72
The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer's disease patients. Int J Geriatr Psychiatry (2002) 1.67
Elaboration on premorbid intellectual performance in schizophrenia: premorbid intellectual decline and risk for schizophrenia. Arch Gen Psychiatry (2005) 1.55
Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology. J Gerontol A Biol Sci Med Sci (2005) 1.55
Time for a shift in focus in schizophrenia: from narrow phenotypes to broad endophenotypes. Br J Psychiatry (2005) 1.55
A genetic and epidemiologic study of cardiovascular disease in Alaska natives (GOCADAN): design and methods. Int J Circumpolar Health (2005) 1.43
Paternal age and intelligence: implications for age-related genomic changes in male germ cells. Psychiatr Genet (2005) 1.42
Higher rates of cigarette smoking in male adolescents before the onset of schizophrenia: a historical-prospective cohort study. Am J Psychiatry (2004) 1.42
Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (2002) 1.41
Postmenopausal uterine bleeding profiles with two forms of continuous combined hormone replacement therapy. Menopause (2002) 1.41
Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry (2004) 1.41
What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it? Schizophr Bull (2008) 1.38
Self-reported attenuated psychotic symptoms as forerunners of severe mental disorders later in life. Arch Gen Psychiatry (2012) 1.35
Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women: Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES). Circulation (2005) 1.34
Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am J Psychiatry (2005) 1.34
Sensitivity of ICD-10 diagnosis of psychotic disorders in the Israeli National Hospitalization Registry compared with RDC diagnoses based on SADS-L. Compr Psychiatry (2005) 1.34
Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res (2012) 1.33
Anxiety disorder and accompanying subjective memory loss in the elderly as a predictor of future cognitive decline. Int J Geriatr Psychiatry (2003) 1.30
NMII forms a contractile transcellular sarcomeric network to regulate apical cell junctions and tissue geometry. Curr Biol (2013) 1.29
C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes: the Strong Heart Study. Circulation (2005) 1.29
Cognitive performance in schizophrenia patients assessed before and following the first psychotic episode. Schizophr Res (2003) 1.26
Cardiovascular disease among Alaska Natives: a review of the literature. Int J Circumpolar Health (2003) 1.23
Blunted prefrontal cortical 18fluorodeoxyglucose positron emission tomography response to meta-chlorophenylpiperazine in impulsive aggression. Arch Gen Psychiatry (2002) 1.22
Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol (2007) 1.22
Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. Eur Neuropsychopharmacol (2009) 1.19
Premorbid intellectual functioning and risk of schizophrenia and spectrum disorders. J Clin Exp Neuropsychol (2006) 1.17
Prospective analysis of mannose-binding lectin genotypes and coronary artery disease in American Indians: the Strong Heart Study. Circulation (2004) 1.16
Relationship between body height and dementia. Am J Geriatr Psychiatry (2005) 1.12
Relationship between premorbid functioning and symptom severity as assessed at first episode of psychosis. Am J Psychiatry (2002) 1.12
Advanced parental age at birth is associated with poorer social functioning in adolescent males: shedding light on a core symptom of schizophrenia and autism. Schizophr Bull (2008) 1.11
Epsilon-sarcoglycan mutations found in combination with other dystonia gene mutations. Ann Neurol (2002) 1.06
Surgical revision after percutaneous mitral repair with the MitraClip device. Ann Thorac Surg (2010) 1.05
Premorbid functioning and treatment response in recent-onset schizophrenia. Br J Psychiatry (2006) 1.04
Premorbid intra-individual variability in intellectual performance and risk for schizophrenia: a population-based study. Schizophr Res (2006) 1.04
Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib. Am Heart J (2009) 1.04
Risperidone in the treatment of schizotypal personality disorder. J Clin Psychiatry (2003) 1.03
Factor analysis of the Cohen-Mansfield Agitation Inventory in three large samples of nursing home patients with dementia and behavioral disturbance. Am J Geriatr Psychiatry (2005) 1.03
Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr Res (2009) 1.00
Social and cognitive functioning, urbanicity and risk for schizophrenia. Br J Psychiatry (2007) 0.99
Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol (2009) 0.98
Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region. Am J Cardiol (2011) 0.97
Public attitudes towards prevention of obesity. PLoS One (2012) 0.94
Measurement of reverse cholesterol transport pathways in humans: in vivo rates of free cholesterol efflux, esterification, and excretion. J Am Heart Assoc (2012) 0.92
Perception of overweight and obesity from different angles: a qualitative study. Scand J Public Health (2012) 0.92
Comments on risk for schizophrenia. Schizophr Res (2005) 0.91
The relationship between risk of hospitalization for schizophrenia, SES, and cognitive functioning. Schizophr Bull (2011) 0.91
Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Schizophr Bull (2013) 0.91
Medical and cost burden of atherosclerosis among patients treated in routine clinical practice. J Med Econ (2010) 0.90
Dilemmas in the (un)veiling of the diagnosis of Alzheimer's disease: walking an ethical and professional tight rope. Patient Educ Couns (2007) 0.90
Are patients enrolled in first episode psychosis drug trials representative of patients treated in routine clinical practice? Schizophr Res (2003) 0.90
Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder. Int J Geriatr Psychiatry (2004) 0.89
Emotional reactions of lay persons to someone with Alzheimer's disease. Int J Geriatr Psychiatry (2004) 0.89
Correlates of cognitive impairment in first episode schizophrenia: the EUFEST study. Schizophr Res (2009) 0.88
A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia. J Clin Psychiatry (2012) 0.88
Are you talking to me?! An exploration of the triadic physician-patient-companion communication within memory clinics encounters. Patient Educ Couns (2012) 0.88
Low prolactin response to fenfluramine in impulsive aggression. J Psychiatr Res (2004) 0.88
Dedifferentiation and substitute strategy: deconstructing the processing-speed impairment in schizophrenia. Schizophr Res (2012) 0.87
Do psychiatric registries include all persons with schizophrenia in the general population? A population-based longitudinal study. Schizophr Res (2012) 0.87
Dexamethasone suppression test findings in subjects with personality disorders: associations with posttraumatic stress disorder and major depression. Am J Psychiatry (2003) 0.87
Expectations, experiences, and tensions in the memory clinic: the process of diagnosis disclosure of dementia within a triad. Int Psychogeriatr (2012) 0.87
Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol (2006) 0.86
Economic cost of Alzheimer disease in Israel. Alzheimer Dis Assoc Disord (2002) 0.86
Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment. J Clin Psychiatry (2002) 0.85
Body mass index and future schizophrenia in Israeli male adolescents. J Clin Psychiatry (2004) 0.85
Subtle cognitive dysfunction in nonaffected siblings of individuals affected by nonpsychotic disorders. Biol Psychiatry (2007) 0.85
Association between functioning in adolescence prior to first admission for schizophrenia and affective disorders and patterns of hospitalizations thereafter. Schizophr Res (2005) 0.84
Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study. Vasc Health Risk Manag (2013) 0.83
Socioeconomic status in relationship to death of vascular disease and late-life dementia. J Neurol Sci (2007) 0.83
Assessing the handwriting process in healthy elderly persons using a computerized system. Aging Clin Exp Res (2006) 0.83
Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months. Dement Geriatr Cogn Disord (2003) 0.82
Self-reported drug abuse in male adolescents with behavioral disturbances, and follow-up for future schizophrenia. Biol Psychiatry (2003) 0.82
CNS infection in childhood does not confer risk for later schizophrenia: a case-control study. Schizophr Res (2010) 0.82
The cost of ipilimumab toxicity: a single-centre analysis. Melanoma Res (2015) 0.81
Physicians' and nurses' preferences in using life-sustaining treatments. Nurs Ethics (2007) 0.81
Impaired reading comprehension and mathematical abilities in male adolescents with average or above general intellectual abilities are associated with comorbid and future psychopathology. J Nerv Ment Dis (2007) 0.81
Acoustic properties of vocally disruptive behaviors in the nursing home. Gerontology (2003) 0.81
Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors. Cardiol Clin (2008) 0.81
Emotional reactions of Arab lay persons to a person with Alzheimer's disease. Aging Ment Health (2009) 0.80
Polish Lipid Association--a strong response to the problem of lipid disorders in Poland and Central and Eastern Europe. J Clin Lipidol (2011) 0.80
Attitudes of the German general population toward early diagnosis of dementia--results of a representative telephone survey. PLoS One (2012) 0.80
Statistical genetic analysis of serological measures of common, chronic infections in Alaska Native participants in the GOCADAN study. Genet Epidemiol (2013) 0.80
Dietitians' attitudes regarding elderly nutritional factors. J Nutr Elder (2006) 0.79
Medical students' attitudes towards overweight and obesity. PLoS One (2012) 0.79
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. Endocr Pract (2017) 0.78